Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Brensocatib

Generic Name: Brensocatib

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₄N_₄O_₄

CAS Number: 1802148-05-5

Unique Ingredient Identifier: 25CG88L0BB

Overview

Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).

Background

Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).

Indication

用于非囊性纤维化支气管扩张症（NCFBE）成人患者的治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 2

Recruiting

Posted: 2024/11/13

Sponsor:Insmed Incorporated

ID:NCT06685835

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Phase 1

Completed

Posted: 2024/04/03

Sponsor:Insmed Incorporated

ID:NCT06344728

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Phase 1

Completed

Posted: 2023/12/21

Sponsor:Insmed Incorporated

ID:NCT06178783

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 2

Active, not recruiting

Posted: 2023/08/28

Sponsor:Insmed Incorporated

ID:NCT06013241

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Phase 1

Completed

Posted: 2023/07/28

Sponsor:Insmed Incorporated

ID:NCT05965570

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Non-Cystic Fibrosis Bronchiectasis Market Expected to Reach USD 7.5 Billion by 2035, Driven by Novel Therapies

2 months ago

The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow from USD 1.7 billion in 2024 to USD 7.5 billion by 2035, representing a robust CAGR of 14.62%.

EMA Evaluates Fast-Track Status for Three Novel Therapeutics from Scholar, Insmed, and Soleno

3 months ago

The European Medicines Agency is reviewing accelerated assessment requests for three innovative drugs - apitegromab, brensocatib, and diazoxide choline - based on their potential major public health impact.

FDA Grants Priority Review to Brensocatib for Non-Cystic Fibrosis Bronchiectasis Treatment

4 months ago

The FDA has accepted Insmed's New Drug Application for brensocatib, setting a PDUFA target action date of August 12 under Priority Review designation.

United Therapeutics' UKidney Xenotransplant Trial Receives FDA Clearance

4 months ago

United Therapeutics received FDA clearance for its IND application to begin clinical trials for UKidney, a gene-edited pig kidney, marking a significant step in xenotransplantation.

Insmed's TPIP and Brensocatib Programs Show Promise in Rare Pulmonary Diseases

4 months ago

Leerink Partners maintains a Buy rating on Insmed with an $85 price target, highlighting significant potential in pulmonary arterial hypertension treatment with TPIP and brensocatib for non-cystic fibrosis bronchiectasis. The company's strategic position in addressing unmet needs in rare pulmonary diseases has sparked acquisition speculation.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy